Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Verrica Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PROCEEDS WILL FULLY RETIRE DEBT FACILITY FROM ORBIMED AND FUND COMPANY OPERATIONS, THEREBY EXTENDING EXPECTED CASH RUNWAY INTO MID-2027 FINANCING ANCHORED BY CALIGAN PARTNERS LP AND PBM CAPITAL, ALONG WITH NEW AND EXISTING INVESTORS; CALIGAN PARTNERS ENTITLED TO DESIGNATE A NEW MEMBER TO VERRICA'S BOARD OF DIRECTORS WEST CHESTER, PA., NOV. 24, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA OR THE COMPANY) (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING AND SELLING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SERIES OF SECURITIES PURCHASE AGREEMENTS FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING, RAISING APPROXIMATELY $50 MILLION IN GROSS PROCEEDS, BEFORE PLACEMENT AGENT FEES AND OFFERING EXPENSES.

VERRICA PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT FINANCING OF $50 MILLION TO RETIRE DEBT AND EXTEND CASH RUNWAY

 COMPANY REPORTS $14.3 MILLION IN REVENUE IN Q3'25, CONSISTING OF $3.6 MILLION IN YCANTH  REVENUE AND $10.7 MILLION OF LICENSE AND COLLABORATION REVENUE 

VERRICA PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

 EXPLORATORY PHASE 2 ANALYSIS SHOWS VERRICA'S NOVEL ONCOLYTIC PEPTIDE, VP-315, REPROGRAMS THE TUMOR MICROENVIRONMENT, INCREASING CYTOTOXIC T-CELL INFILTRATION AND REDUCING IMMUNOSUPPRESSIVE T-REGULATORY CELLS   FINDINGS PROVIDE MECHANISTIC IMMUNOLOGIC SUPPORT FOR CLINICAL EFFICACY PREVIOUSLY REPORTED, INCLUDING 97% CALCULATED OBJECTIVE RESPONSE RATE AND 51% COMPLETE HISTOLOGIC CLEARANCE RATE   COUPLED WITH VP-315'S PREVIOUSLY REPORTED SAFETY PROFILE, THESE RESULTS HIGHLIGHT VP-315'S POTENTIAL AS A FIRST-IN-CLASS, NON-SURGICAL IMMUNOTHERAPEUTIC OPTION FOR PATIENTS WITH BASAL CELL CARCINOMA  WEST CHESTER, PA., NOV. 10, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING AND SELLING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THE PRESENTATION OF NEW DATA FROM ITS PHASE 2 STUDY EVALUATING VP-315 (RUXOTEMITIDE), A NOVEL ONCOLYTIC PEPTIDE IMMUNOTHERAPY, AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING WHICH TOOK PLACE NOVEMBER 59, 2025, IN NATIONAL HARBOR, MARYLAND.

VERRICA PHARMACEUTICALS PRESENTS NEW DATA ON VP-315 FROM ITS PHASE 2 CLINICAL TRIAL IN BASAL CELL CARCINOMA AT THE 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF VERRICA PHARMACEUTICALS, INC. (NASDAQ: VRCA) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN VERRICA STOCK AND ARE A LONG-TERM SHAREHOLDER, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO LEARN MORE ABO.

HALPER SADEH LLC ENCOURAGES VERRICA PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

 EMA CONCLUDES THAT THE PRIMARY ENDPOINT AND SUPPORTIVE SECONDARY ENDPOINTS FROM PRIOR SUCCESSFUL PHASE 3 STUDIES CONDUCTED IN THE U.S. AND JAPAN ARE ADEQUATE TO SUPPORT A FILING FOR THE APPROVAL OF YCANTH  IN THE EU AND THAT NO ADDITIONAL PHASE 3 STUDIES ARE REQUIRED 

VERRICA PHARMACEUTICALS RECEIVES POSITIVE FEEDBACK FROM THE EUROPEAN MEDICINES AGENCY (EMA) SUPPORTING A CLEAR REGULATORY PATH FORWARD TO FILE FOR APPROVAL OF YCANTH IN THE EUROPEAN UNION

WEST CHESTER, PA. , OCT. 07, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. ("VERRICA") (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING AND SELLING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THAT IT WILL BE PRESENTING BOTH AN ORAL PRESENTATION AND A POSTER ON VP-315, ITS ONCOLYTIC PEPTIDE FOR THE TREATMENT OF BASAL CELL CARCINOMA (BCC), AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND.

VERRICA PHARMACEUTICALS TO PRESENT NEW DATA ON VP-315 FROM ITS PHASE 2 TRIAL IN BASAL CELL CARCINOMA (BCC) AT THE 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

 APPROVAL TRIGGERS $10 MILLION CASH MILESTONE PAYMENT TO VERRICA   YCANTH  APPROVAL IN JAPAN ADDRESSES SIGNIFICANT UNMET NEED OF PATIENTS WITH MOLLUSCUM   VERRICA MAINTAINS OWNERSHIP OF GLOBAL RIGHTS TO YCANTH FOR ALL INDICATIONS IN ALL TERRITORIES OUTSIDE OF JAPAN  WEST CHESTER, PA., SEPT. 19, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING AND SELLING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THAT ITS DEVELOPMENT PARTNER, TORII PHARMACEUTICAL CO. LTD.

VERRICA PHARMACEUTICALS ANNOUNCES THAT DEVELOPMENT PARTNER, TORII PHARMACEUTICAL, RECEIVES APPROVAL FOR YCANTH (TO-208) IN JAPAN FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM

WEST CHESTER, PA., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA) (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING AND SELLING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THAT JAYSON RIEGER, PHD, MBA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF VERRICA PHARMACEUTICALS, WILL PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY.

VERRICA PHARMACEUTICALS TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

 COMPANY REPORTS $12.7 MILLION IN REVENUE IN Q2'25, CONSISTING PRIMARILY OF $4.5 MILLION IN YCANTH  REVENUE, NET, REFLECTING SEQUENTIAL GROWTH OF 32.5% OVER Q1'25 AND $8.0 MILLION IN MILESTONE REVENUE FROM TORII PHARMACEUTICAL 

VERRICA PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

WEST CHESTER, PA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- VERRICA PHARMACEUTICALS INC. (VERRICA OR THE COMPANY) (NASDAQ: VRCA), A DERMATOLOGY THERAPEUTICS COMPANY DEVELOPING MEDICATIONS FOR SKIN DISEASES REQUIRING MEDICAL INTERVENTIONS, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 4:30 P.M. ET ON TUESDAY, AUGUST 12, 2025, TO DISCUSS THE COMPANY'S FINANCIAL RESULTS FOR THE SECOND QUARTER ENDING JUNE 30, 2025, AND PROVIDE A CORPORATE UPDATE.

Verrica Pharmaceuticals Inc.

VRCA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Verrica Pharmaceuticals Inc.

VRCA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VRCA